Research Summaries

Patients with HIV have up to double the risk of atherosclerotic cardiovascular disease compared with the general population.

In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...

The FDA has approved empagliflozin, and empagliflozin and hydrochloride to help manage type 2 diabetes in pediatric patients.

Researchers evaluated the mortality risk of patients with polycystic ovarian syndrome and the risk of death associated with disease comorbidities.

Researchers sought to establish the global disease burden of sickle cell disease and its mortality rate.

The FDA has approved a new buprenorphine treatment option for people with opioid use disorder following clinical trials that tested its safety and efficacy.

The FDA has examined the results of a recent confirmatory trial to verify the clinical benefit of an amyloid beta-directed antibody for the treatment of Alzheimer disease.

The USPSTF has updated its recommendations on screening adults for major depressive disorder (MDD) and suicide risk.

Following two trials, the FDA has approved the first treatment for molluscum contagiosum.

Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.